Clinical Trial Update: High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of Phase 1/2 testing of high-dose, absorbed-dose-adjusted 90Y-ibritumomab tiuxetan with peripheral blood stem …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Lund University Hospital | Conditions: B-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED